Alzheimer’s in China: a model estimates the gap between eligibility and access to anti-amyloid treatments

How many people could access amyloid-targeting treatments in China? A meta-analysis combined with modeling highlights the importance of consultations, diagnosis and biomarker testing in this estimate. The model yields 39,825 potentially eligible people under current conditions, compared with 14.17 million when these constraints are removed. These figures are estimates, not a count of individually assessed patients.

Diagram of the consultation, diagnosis and biomarker testing steps used to estimate eligibility for anti-amyloid treatments in China.
MindsetEditorial illustration, not study data.

A synthesis of 27 observational studies

The researchers pooled 27 population studies involving 312,204 people aged at least 60 in mainland China. They searched four bibliographic databases for studies published between January 2020 and August 2026. Most included studies were of moderate methodological quality.

The pooled prevalence was 21.21% for mild cognitive impairment and 4.72% for Alzheimer’s disease. However, results varied considerably across studies: statistical heterogeneity reached 99.7% and 99.8%, respectively. These averages therefore do not uniformly describe all Chinese populations in this age group.

Access to diagnosis substantially changes the estimate

The authors incorporated these data into a stepwise model accounting for healthcare use, clinical diagnosis, biomarker testing and amyloid positivity. The aim was to estimate the population potentially eligible for amyloid-targeting treatments at the early symptomatic stage of Alzheimer’s disease.

Under the current conditions assumed by the model, this population was estimated at 39,825 people. When constraints on consultations, diagnosis and testing were removed, the estimate reached 14.17 million. This gap illustrates how sensitive the result is to assumptions about access to care. It does not mean that 14.17 million people already have a confirmed indication for treatment.

A planning tool, not evidence of efficacy

The main value of this work lies in healthcare planning: diagnostic capacity, resource allocation and reimbursement decisions. This is not a trial comparing an anti-amyloid treatment with a placebo, and these estimates measure neither its clinical benefit nor its adverse effects.

The authors performed sensitivity analyses to explore uncertainty. However, the substantial heterogeneity across studies and the lack of detailed age-specific data limit the precision of the projections. The results concern mainland China and cannot be directly extrapolated to France.

Limitations to keep in mind

Only the PubMed abstract was consulted, not the full text. The estimates rely on highly heterogeneous observational studies and model assumptions. Age-specific data are limited. Funding and conflicts of interest could not be verified from the dossier.

What we can take away

This study suggests that access to consultations and testing strongly influences the number of people identified as potentially eligible. It cannot determine eligibility or expected benefit for an individual.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.